Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Receivables (2021 - 2023)

Historic Receivables for Inhibikase Therapeutics (IKT) over the last 3 years, with Q2 2023 value amounting to $79604.0.

  • Inhibikase Therapeutics' Receivables rose 111495.73% to $79604.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $79604.0, marking a year-over-year increase of 111495.73%. This contributed to the annual value of $39881.0 for FY2022, which is 6379.1% down from last year.
  • As of Q2 2023, Inhibikase Therapeutics' Receivables stood at $79604.0, which was up 111495.73% from $64521.0 recorded in Q1 2023.
  • Inhibikase Therapeutics' Receivables' 5-year high stood at $110141.0 during Q4 2021, with a 5-year trough of $6552.0 in Q2 2022.
  • In the last 3 years, Inhibikase Therapeutics' Receivables had a median value of $47976.0 in 2022 and averaged $51788.1.
  • Per our database at Business Quant, Inhibikase Therapeutics' Receivables plummeted by 6379.1% in 2022 and then soared by 111495.73% in 2023.
  • Inhibikase Therapeutics' Receivables (Quarter) stood at $110141.0 in 2021, then tumbled by 63.79% to $39881.0 in 2022, then soared by 99.6% to $79604.0 in 2023.
  • Its Receivables was $79604.0 in Q2 2023, compared to $64521.0 in Q1 2023 and $39881.0 in Q4 2022.